From blood-based biomarkers to AI-powered tools, discover how 9 innovations are being tested in the NHS to speed up dementia ...

All NICE products on prostate cancer. Includes any guidance, advice and quality standards.

This guideline has been updated and replaced by epilepsies in children, young people and adults ...

Evidence-based recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-low metastatic or unresectable breast cancer after chemotherapy in adults. This guidance updates and replaces NICE ...

Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, ARCHITECT STAT High Sensitive Troponin-I and AccuTnI+3 assays) Diagnostics ...

There is a commercial access agreement for dupilumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact GB-PatientAccess@sanofi.com ...

This guide describes the methods and processes, including expected timescales, that NICE follows when producing technology appraisal and highly specialised technologies guidance. The methods and ...

intermittently scanned continuous glucose monitoring. HCL systems are only recommended if they are procured at a cost-effective price agreed by the companies and NHS England, and implemented following ...

This guidance has been updated and replaced by NICE technology appraisal guidance 736 ...

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years Technology appraisal guidance TA554 Published: 21 December 2018 ...

This guideline covers nutrition and weight management in pregnancy for anyone who may become pregnant, is planning to become pregnant or is already pregnant, and nutrition in children up to 5 years.

Evidence-based recommendations on 12 standardised quality betula verrucosa pollen sublingual lyophilisate (12 SQ-Bet SLIT; Itulazax) for treating moderate to severe allergic rhinitis or conjunctivitis ...